Evaluated for: Wet macular degeneration
How it works: Bevasiranib represents the first drug in a promising new class of experimental medical treatments. It is a small interfering RNA (siRNA) drug, which silences the genes that produce Vascular Endothelial Growth Factor (VEGF), a protein that promotes blood vessel growth. The treatment slows the growth and leakage of abnormal blood vessels that are associated with the wet form of macular degeneration. The drug is injected directly into the eye.
Most common side effects: Swelling and inflammation at the injection site. No adverse side effects have yet been reported; however, this experimental drug is still in clinical trials.
A thoughtful evaluation must be performed by a physician before taking any medications, over-the-counter drugs, supplements, or herbs. The American Health Assistance Foundation does not endorse any of these medications, vitamins, or herbs. A qualified physician should make an informed decision based on each person's medical history and current prescriptions. The medication summaries provided do not include all of the information important for patient use and should not be used as a substitute for professional medical advice. The prescribing physician should be consulted concerning any questions that you have.
The information provided in this section of our website was obtained from the National Institutes of Health (NIH)/National Eye institute (NEI), the Food and Drug Administration (FDA), the National Library of Medicine, and research scientists specializing in macular degeneration.
Reviewed on 2/14/2008